The Food and Drug Administration (FDA) approval of Luxturna (voretigene neparvovec-rzyl) for treatment of RPE65-related inherited retinal dystrophy (RPE65-IRD) in 2017 was the first regulatory approval of an in vivo gene therapy in the United States (1). This evidence concerns the gene RPE65 and inherited retinal dystrophy.